Low-Grade Glioma (LGG) Registry Aims

1. Study inherited genes, environment, and lifestyle factors to understand if they are related to LGG risks & outcomes
2. Study genetic and molecular characteristics of glioma tumors
3. Study symptoms & quality of life

Elizabeth B. Claus, MD PhD (center) founded the LGG Registry in 2016 to advance the study of this rare disease. The OPTIMUM study was then created and funded by the NCI's Cancer Moonshot Initiative to better understand recurrent gliomas.

OPTIMUM is led by Dr. Claus (Yale Univ., Brigham & Women's Hosp.), Bethany Kwan, PhD MSPH (Univ. of Colorado), and Roel Verhaak, PhD (Yale Univ.) as part of the Participant Engagement and Cancer Genomic Sequencing (PE-CGS) Network.

Contact Us

Please do not hesitate to reach out to us if you have any questions.

Together, we can fill knowledge gaps about low-grade glioma brain tumors, allowing us to guide future treatments.

glioma@yale.edu

gliomaregistry.org

(203) 785 6415

@gliomaregistry

Yale Human Investigation Committee #1604017628

The International Low-Grade Glioma Registry

An international effort to advance the study of low grade glioma

Website: gliomaregistry.org
Email: glioma@yale.edu
Twitter: @gliomaregistry
Office: 203.785.6415
Fax: 203.785.6912

What is the study about?

Little is known about low grade glioma (LGG), a slow growing brain tumor. To learn more about gliomas, we are asking adults diagnosed with LGG to join this study to discover why some people develop glioma while other people do not.



Who can join the registry?

The Registry recruits people to participate from across the globe, via social media and at a number of different hospitals, including Dana Farber Cancer Institute and Yale New Haven Hospital.

1. **Must be currently between ages 21-79 (regardless of age at diagnosis)**
2. **Must have a confirmed pathology for grade 2 or 3 glioma (via surgery)**
3. **No restrictions based on sex, gender, race/ethnicity, or geography. However, OPTIMUM participants must receive their care in the US.**
4. **Those with recurrent LGG (2+ surgeries) may be eligible for OPTIMUM, a study within the registry**

After you enroll in the Low Grade Glioma Registry, we review your pathology report to confirm whether you are eligible for the study.

What to expect

Participation in the Low-Grade Glioma Registry involves a few steps

- Complete a consent form

- Share your health information via secure health server (Hugo Health)

- Complete a questionnaire (30 min)

- Provide samples (i.e., saliva or blood spot) via mail

- Sample genes will be analyzed

- Genetic analysis results returned (OPTIMUM only). You may discuss these with your provider.

With your permission, we access tumor samples from prior surgeries to study these tumors as well.

You may opt out of the study at any point. Your information will be stored confidentially. Please refer to our consent form for further details.